Главная
Рынки
Графики и идеи
Алготрейдинг
Новости
Store
Брокеры
Скачать
Экономический календарь
Торговые сигналы
Вебтерминал
Нажмите
/
для поиска: @user, $symbol, ...
Поиск
Вход
Создать аккаунт
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
KRRO
#3223
Korro Bio, Inc. Common Stock
12.130
0
+4.39%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
Годовой диапазон
Дневное изменение
+4.39%
Месячное изменение
+6.22%
6-месячное изменение
-68.82%
Годовое изменение
-68.82%
Предыдущее закрытие
11.620
0
Open
12.130
0
Bid
Ask
Low
12.130
0
High
12.130
0
Объем
27
Рынки
Рынок акций США
Здравоохранение
KRRO
Open full chart
Financials
Overview
Отчетность
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
9.37 M
9.39 M
9.39 M
9.39 M
9.42 M
—
Valuation ratios
Enterprise value
249.88 M
301.79 M
99.34 M
83.68 M
426.84 M
911.66 M
Price to earnings ratio
0.24
-4.06
-1.85
-1.28
-5.1
-12.29
Price to sales ratio
—
149.54
—
—
60.02
—
Price to cash flow ratio
1.68
5.65
2.56
1.73
6.54
16.48
Price to book ratio
0.06
0.49
0.06
0.04
0.15
0.74
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.09
0.09
0.12
0.14
0.11
0.46
Return on equity %
0.12
0.13
0.17
0.22
0.18
0.71
Return on invested capital %
-102.59
-71.83
-81.21
-127.88
-99.97
-380.89
Gross margin %
—
100
100
100
100
400
Operating margin %
—
-1 014.53
-981.18
-1 863.15
-1 764.86
-5 623.72
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
933.47
917.14
1 765.07
1 656.97
5 272.64
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
11.23
8.79
9.41
5.98
6.71
30.89
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
0.01
0.01
0.01
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.83
0.84
2.61
2.05
1.83
7.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
15.62
6.24
12.25
10.27
9.85
38.6
Net current asset value per share
17.42
14.74
12.92
10.93
10.46
49.06
Tangible book value per share
76.43
77.72
76.61
79.53
81.65
315.52
Working capital per share
15.87
13.07
11.55
9.1
8.9
42.62
Book value per share
76.43
77.72
76.61
79.53
81.65
315.52
Новости
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates
코로 바이오, 고암모니아혈증 프로그램 잠재력에 Clear Street, 투자의견 상향
Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
코로 바이오, HC 웨인라이트, 신약 잠재력에 매수 등급으로 상향
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential
파이퍼 샌들러, 코로 바이오 투자의견 ’비중확대’로 상향...UCD 치료제 주목
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential
Korro Bio, Inc. (KRRO) Analyst/Investor Day - Slideshow (NASDAQ:KRRO) 2026-01-28
윌리엄 블레어, 코로 바이오에 대해 ’Market Perform’ 등급 유지
레이먼드 제임스, 코로 바이오에 ’시장 수익률’ 등급 유지